Hair therapy advertisements claim to use a mix of fallopia multiflora, ginseng, angelica sinensis, and vitex rotundifolia for hair growth. A user dismisses it as fake.
Bimatoprost (Latisse) may help with hair thinning but is expensive and less effective than minoxidil or finasteride. Combining treatments like minoxidil, finasteride, and possibly RU58841 could be more effective for hair loss.
The conversation discusses a comparison table for a spray combining Minoxidil and Finasteride for hair loss treatment in the UK. Specific treatments mentioned are Minoxidil (Min) and Finasteride (Fin).
The conversation discusses using very low dose topical finasteride to achieve specific serum DHT reduction percentages. It concludes that finasteride dosage increases linearly between 5-30% DHT reduction but requires exponential increases for reductions up to 70%.
Hair cloning and new treatments like ET-02, Veradermics (vdphl01), and wound-induced hair neogenesis show promise but are not yet widely available. Current effective treatments include minoxidil, finasteride, and dutasteride, with early intervention being crucial for better outcomes.
User discusses Latanoprost as potential hair loss treatment and considers combining it with oral minoxidil for better results. Seeking opinions on effectiveness and expense.
Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.
Red light therapy for hair loss is controversial, with mixed results reported. Its effectiveness may depend on device quality and proper wavelength, and it is often used with minoxidil and finasteride.
Capilia Longa and Scandinavian Biolabs are discussed, with skepticism about their effectiveness and value. The conversation suggests avoiding these products due to high cost and perceived lack of results.
Hair loss treatments like GT20029, pyrilutamide, and Follica show promise in 2022. Phase 1 and 2 trials are underway, and new hair growth studies have been published.